The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-7022-913X
dc.authorid0000-0001-5057-0405
dc.contributor.authorBulur, Işıl
dc.contributor.authorBülbül Başkan, Emel
dc.contributor.authorÖzdemir, Mustafa
dc.contributor.authorBalevi, Ali
dc.contributor.authorKocatürk Göncü, Emek
dc.contributor.authorKıvanç Altunay, İlknur
dc.contributor.authorGönül, Müzeyyen
dc.contributor.authorErgin, Can
dc.contributor.authorErtam, İlgen
dc.contributor.authorKaya Erdo?an, Hilal
dc.contributor.authorBilgin, Muzaffer
dc.contributor.authorErdem, Mustafa Teoman
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:17Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:17Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıklar Ana Bilim Dalı
dc.description.abstractIntroduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients. Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months. Results: The mean weekly urticarial activity score (UAS7) after omalizumab treatment improved significantly compared to the pretreatment score (p <0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab’s treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 ± 6.15 before treatment and decreased to 3.55 ± 3.60 6 months after treatment (p <0.001). No side effects were reported in 89.4% (118) of the patients. Conclusion: This study showed that UAS7 decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data.
dc.identifier.citationBulur, I., Bülbül Başkan, E., Özdemir, M., Balevi, A., Kocatürk Göncü, E., Kıvanç Altunay, İ. ... Erdem, M. T. (2018). The efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey. Acta Dermatovenerologica Alpina, Pannonica et Adriatica, 27(3), 121-126. https://dx.doi.org/10.15570/actaapa.2018.25
dc.identifier.doi10.15570/actaapa.2018.25
dc.identifier.endpage126
dc.identifier.issn1318-4458
dc.identifier.issn1581-2979
dc.identifier.issue3
dc.identifier.scopusqualityN/A
dc.identifier.startpage121
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1120
dc.identifier.urihttps://dx.doi.org/10.15570/actaapa.2018.25
dc.identifier.volume27
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSlovenian Medical Society
dc.relation.ispartofActa Dermatovenerologica Alpina, Pannonica et Adriaticaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChronic Spontaneous Urticaria
dc.subjectDermatology Life Quality
dc.subjectOmalizumab
dc.subjectSide Effect
dc.subjectUAS7
dc.titleThe efficacy and safety of omalizumab in refractory chronspontaneous urticaria: Real-life experience in Turkey
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Özdemir, M..pdf
Boyut:
7.77 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu